854 related articles for article (PubMed ID: 15469413)
21. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
[TBL] [Abstract][Full Text] [Related]
22. The value of peripheral blood eosinophil count in predicting in-stent restenosis in patients with stable angina pectoris undergoing drug eluting stenting.
Hajizadeh R; Ghaffari S; Separham A; Shokouhi B; Kavandi H; Pourafkari L; Nader ND
Rom J Intern Med; 2017 Dec; 55(4):229-236. PubMed ID: 28672766
[TBL] [Abstract][Full Text] [Related]
23. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
24. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
[TBL] [Abstract][Full Text] [Related]
25. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.
Nishihira K; Shibata Y; Ishikawa T; Nomura K; Nakama T; Mine D; Inoue Y; Ashikaga K; Kuriyama N; Matsuyama A; Imamura T; Asada Y; Kitamura K
Circ J; 2010 Nov; 74(11):2329-33. PubMed ID: 20890050
[TBL] [Abstract][Full Text] [Related]
26. Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients.
Maheronnaghsh M; Niktab I; Enayati S; Amoli MM; Hosseini SK; Tavakkoly-Bazzaz J
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1137-1147. PubMed ID: 33712363
[TBL] [Abstract][Full Text] [Related]
27. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.
Xu B; Qian J; Ge J; Wang J; Chen F; Chen J; Wei M; Chen Y; Yang Y; Gao R;
Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():624-9. PubMed ID: 26775079
[TBL] [Abstract][Full Text] [Related]
28. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
[TBL] [Abstract][Full Text] [Related]
29. Acute coronary syndrome - a frequent clinical manifestation of bare metal in-stent restenosis.
Drozd J; Wójcik J; Małek R; Korona B; Zapolski T; Wysokiński A
Kardiol Pol; 2010 Jun; 68(6):637-45. PubMed ID: 20806192
[TBL] [Abstract][Full Text] [Related]
30. Relationship of interleukin-6-572C/G promoter polymorphism and serum levels to post-percutaneous coronary intervention restenosis.
Gao J; Liu Y; Cui RZ; Mao YM; Zhou J; Chen Q; Zhao FM; Yang GM
Chin Med J (Engl); 2013 Mar; 126(6):1019-25. PubMed ID: 23506572
[TBL] [Abstract][Full Text] [Related]
31. Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis.
Ganesh SK; Joo J; Skelding K; Mehta L; Zheng G; O'Neill K; Billings EM; Helgadottir A; Andersen K; Thorgeirsson G; Gudnason T; Geller NL; Simari RD; Holmes DR; O'Neill WW; Nabel EG
BMC Med Genomics; 2011 Feb; 4():20. PubMed ID: 21356094
[TBL] [Abstract][Full Text] [Related]
32. Genetic variants in CCNB1 associated with differential gene transcription and risk of coronary in-stent restenosis.
Silvestre-Roig C; Fernández P; Mansego ML; van Tiel CM; Viana R; Anselmi CV; Condorelli G; de Winter RJ; Martín-Fuentes P; Solanas-Barca M; Civeira F; Focaccio A; de Vries CJ; Chaves FJ; Andrés V
Circ Cardiovasc Genet; 2014 Feb; 7(1):59-70. PubMed ID: 24395923
[TBL] [Abstract][Full Text] [Related]
33. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.
Auffret V; Berland J; Barragan P; Waliszewski M; Bonello L; Delarche N; Furber A; Albert F; Carrié D; Eltchaninoff H; Pansieri M; Schneeberger M; Piot C; Marcollet P; Bedossa M
Int J Cardiol; 2016 Jan; 203():690-6. PubMed ID: 26583844
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
35. Pathological features of in-stent restenosis after sirolimus-eluting stent versus bare metal stent placement.
Abe S; Yoneda S; Kanaya T; Oda K; Nishino S; Kageyama M; Taguchi I; Masawa N; Inoue T
Cardiovasc Pathol; 2012; 21(2):e19-22. PubMed ID: 21489821
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
37. Description of Pantera Lux paclitaxel-releasing balloon and preliminary quantitative coronary angiography (QCA) results at six months in patients with coronary in-stent restenosis.
Hehrlein C; Richardt G; Wiemer M; Schneider H; Naber C; Hoffmann E; Dietz U
EuroIntervention; 2011 May; 7 Suppl K():K119-24. PubMed ID: 22027721
[TBL] [Abstract][Full Text] [Related]
38. Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis.
Feres F; Muñoz JS; Abizaid A; Albertal M; Mintz GS; Staico R; Centemero M; Mattos LA; Maldonado G; Tanajura LF; Chaves A; Pinto I; Abizaid AS; Seixas AC; Vaz VD; Sousa A; Sousa JE
Am J Cardiol; 2005 Dec; 96(12):1656-62. PubMed ID: 16360353
[TBL] [Abstract][Full Text] [Related]
39. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome after management of unprotected left main in-stent restenosis after bare metal or drug-eluting stents.
Chen SL; Xu B; Mintz G; Ye F; Zhang JJ; Kan J; Sun XW; Zhang AP; Chen JG; Qian J; Kwan TW
Chin Med J (Engl); 2010 Apr; 123(7):794-9. PubMed ID: 20497666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
